Medical testing leader Biomnis is investing €3m in the Irish pathology sector. This includes the acquisition of Euromedic Lablink and the launch of new medical tests by its subsidiary.
Euromedic Lablink will now join forces with Claymon Biomnis to create a new enlarged group, Biomnis Ireland. As a result of the acquisition, Biomnis Ireland will also become the largest workplace health screening provider in the Irish market.
Biomnis is beginning a major test repatriation scheme to Ireland which will see a suite of test processes transferred from Biomnis labs in France to the Irish laboratory, based at Sandyford in Co Dublin.
The company will also conduct a significant technology upgrade as part of the deal, which will lead to a 30pc increase in the amount of testing currently carried out within its Dublin laboratories.
The deal is the first major consolidation within the independent medical laboratory services sector, creating the largest private provider in the Irish market.
Biomnis Ireland is wholly owned by the Biomnis Group, which is one of the top 3 European medical laboratory groups, processing more than 10 million specialised tests annually, for clients in 40 countries.
“This deal represents a vote of confidence in Ireland by one of the largest European medical testing groups,” John O’Sullivan, managing director of Biomnis Ireland, said.
“Claymon Biomnis has established a significant presence in the Irish laboratory testing sector over the last 19 years through the successful development of strong partnerships with many public and private hospitals and clinics throughout the country.
Acquisition
“The acquisition of Euromedic Lablink, a recognised medical testing service provider in Ireland since 2001, is a natural fit and will allow us to capitalise on the synergies between our two companies. It will also allow the newly formed group, Biomnis Ireland, to greatly enhance and broaden its service offering to healthcare professionals in both the public and private sectors.”
“The additional investment by Biomnis in the Irish market, as well as their decision to transfer to our laboratory a suite of test processes, such as Vitamin D Analysis, Autoimmune Serology and Allergy Testing, which are typically carried out at their state-of-the-art laboratories in France, also illustrates the group’s confidence in Ireland as an investment location. These two developments recognise both the highly-skilled and educated workforce that continues to make Ireland an attractive destination to locate as well as the opportunities that exist in this specialised sector to expand and grow now and into the future.
“As more than 70pc of all decisions about patient diagnosis rest on medical test results, our core purpose has always been to help healthcare professionals diagnose, monitor and treat patient illness. We are very excited that as Biomnis Ireland we can play an increasingly prominent role in the fight against human disease.”
The announcement was today welcomed by the Minister for Enterprise, Trade and Innovation Batt O’Keeffe TD.
“Biomnis is a world-renowned French firm with a strong track record in product innovation. The acquisition of Euromedic Lablink, coupled with the decision to locate test procedures in Dublin and significantly upgrade their technology capability, dramatically strengthens Biomnis Ireland’s clinical expertise here. Biomnis Ireland is now well positioned for strong growth in the pathology and health screening sectors here and I wish the firm every success,” said O’Keeffe.
The newly formed Biomnis Ireland will employ more than 100 people at its laboratories in Dublin. All existing contracts with customers of Lablink and Claymon Biomnis will be maintained and continued as the group looks forward to servicing the current and future needs of healthcare professionals in Ireland.
With revenues of nearly €250m a year, Biomnis employs 60 full-time medical pathologists and more than 1,600 scientific, technical and support staff.
